Showing 1,268 results

Filters Content type: News, Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

The search for a cure

Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Editor's pick
Seeking Alpha
10 March 2015
The search for a cure

We may need to combine many approaches to achieve a cure, delegates hear

News
9 March 2015
New & experimental HIV treatments

HIV attachment inhibitor BMS-663068 safe and effective in phase 2b study

News
4 March 2015
HIV treatment

Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

News
27 February 2015
New & experimental HIV treatments

48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Editor's pick
Bristol Myers Squibb press release
26 February 2015
New & experimental HIV treatments

HIV maturation inhibitor BMS-955176 looks promising in early study

News
26 February 2015
The search for an HIV prevention vaccine

Experimental AIDS Drug Stirs Talk Of Vaccine 'Alternative'

Editor's pick
Huffington Post
19 February 2015
New & experimental HIV treatments

CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy

Editor's pick
CytoDyn press release
5 February 2015
Neurological & cognitive problems

Researchers identify key mechanisms underlying HIV-associated cognitive disorders

Editor's pick
Medical Xpress
4 February 2015
New & experimental HIV treatments

Treatment of the First HIV Positive Patient in ABIVAX's Phase IIa Clinical Trial With ABX464

Editor's pick
ABIVAX press release
2 February 2015
New & experimental HIV treatments

PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Editor's pick
Janssen press release
30 January 2015
New & experimental HIV treatments

U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Editor's pick
Bristol-Myers Squibb press release
30 January 2015
Pharmaceutical industry

Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

Editor's pick
Street Insider
26 January 2015
Resistance

Exploring possible treatment options after virological failure with raltegravir

Editor's pick
CATIE
21 January 2015
New & experimental HIV treatments

New anti HIV drug dolutegravir is effective at low doses

Editor's pick
MMD Newswire
21 January 2015
Access to healthcare

Hepatitis C drug delayed by NHS due to high cost

Editor's pick
The Guardian
16 January 2015
New & experimental HIV treatments

Janssen launches HIV combo Rezolsta in UK

Editor's pick
Pharma Times
15 January 2015
New & experimental HIV treatments

Argos tanks as its HIV immunotherapy flunks Phase II

Editor's pick
FierceBiotech
12 January 2015
Pharmaceutical industry

Gilead, Janssen Expand HIV Combo Collaborations

Editor's pick
Genetic Engineering & Biotechnology News
30 December 2014
Pharmaceutical industry

Gilead Sciences, Inc. Can't Do It Alone

Editor's pick
Motley Fool
30 December 2014
New & experimental HIV treatments

European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Editor's pick
Janssen
25 November 2014
New & experimental HIV treatments

HIV Drug Development Pipeline Update, Fall 2014 Edition

Editor's pick
The Body Pro
17 November 2014
New & experimental HIV treatments

Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

News
10 November 2014
New & experimental HIV treatments

Doravirine works as well as efavirenz with fewer CNS side-effects

News
10 November 2014